ACTOnco, ACTOnco IVD
Dec 2022
718d
Act Genomics
1
Total
1
Cleared
0
Denied
Act Genomics — FDA 510(k) Submissions
Act Genomics has submitted 1 FDA 510(k) premarket notifications since 2022, of which 1 received clearance as substantially equivalent to a predicate device.
The company's most frequent device categories include Next Generation Sequencing Based Tumor Profiling Test . Use the specialty filter in the sidebar to narrow results.
1 devices